Thomas Civik
CIK 1723092 · CEO & Chairman of the Board · last filed 2026-09-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RPTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
150 SECOND STREET
CAMBRIDGE, MA 02141
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PYXS | CEO & Chairman of the Board | 221,886 | $1.71 | $378.3K | $200.0K | 9 | 2026-09-08 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 0 | $2.65 | $0 | $210.6K | 6 | 2026-01-28 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | President and CEO | 0 | $38.00 | $0 | $0 | 3 | 2021-04-19 |
| Foundation Medicine, Inc. (FMI) Delisted | Chief Commercial Officer | 33,421 | — | — | $0 | 1 | 2018-01-03 |
Recent Filings · Page 2 of 2
20 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-04-04 | PYXS | Grant (A) | +66,831 | $0 | EDGAR |
| 2021-11-19 | PYXS | Buy (P) | +15,700 | $200.0K | EDGAR |
| 2021-11-18 | Repare Therapeutics Inc. (RPTX) Delisted | Buy (P) | +7,500 | $210.6K | EDGAR |
| 2021-10-12 | PYXS | Grant (A) | — | $0 | EDGAR |
| 2021-09-09 | Repare Therapeutics Inc. (RPTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-04-19 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Disp (D) | −68,971 | -$2.62M | EDGAR |
| 2021-04-13 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Tax (F) | −11,088 | -$420.7K | EDGAR |
| 2020-04-14 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Grant (A) | +75,000 | $0 | EDGAR |
| 2018-08-02 | — | Other (J) | −33,421 | -$4.58M | |
| 2018-01-03 | Foundation Medicine, Inc. (FMI) Delisted | Grant (A) | +33,421 | $2.28M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.